Related Experiment Video
Updated: Jun 25, 2026
08:54
Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Clinical indications for newer antifungal agents
Nina Naeger-Murphy1, James C Pile
1Division of Infectious Diseases, Case Western Reserve University at MetroHealth Medical Center, Cleveland, Ohio 44109, USA.
Journal of Hospital Medicine
|February 17, 2009
Summary
New antifungal drugs like echinocandins and triazoles offer more treatment options for serious fungal infections. This review examines their evidence and role in conditions such as invasive candidiasis and aspergillosis.
Area of Science:
- Infectious Diseases
- Pharmacology
- Mycology
Background:
- Serious fungal infections pose significant treatment challenges.
- Recent advancements have introduced novel systemic antifungal agents.
- Existing treatment options have limitations in efficacy and resistance.
Purpose of the Study:
- To review the evidence for newer antifungal medications.
- To outline the clinical utility of novel antifungal agents.
- To guide the use of new antifungals in specific clinical scenarios.
Main Methods:
- Systematic review of published literature.
- Analysis of clinical trial data for new antifungal agents.
- Evidence synthesis on efficacy and safety.
Main Results:
- New echinocandin and triazole antifungals demonstrate significant efficacy.
- Voriconazole and posaconazole represent advances in azole therapy.
- Echinocandins (caspofungin, micafungin, anidulafungin) offer new treatment avenues.
Conclusions:
- Novel systemic antifungal agents expand therapeutic options for invasive mycoses.
- Careful consideration of institutional policies and cost is necessary.
- These agents are crucial for managing challenging fungal infections like invasive candidiasis and aspergillosis.
Related Concept Videos
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:28Fungal Phylum Microsporidia
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...